MAPT and metabolic disease: Kallistatin, a serine proteinase inhibitor increased in patients with obesity, prediabetes and diabetes,51, 52 was shown to modulate systemic metabolism and promote amyloid plaque deposition and tau phosphorylation, thus linking metabolic disorders with neurodegenerative processes.53